Lisa Speiser

Dr. Lisa Speiser


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLisa Speiser
Lisa Speiser
SKSabirah Kasule
Sabirah Kasule
CHCarina M Hall
Carina M Hall
JSJason W Sahl
Jason W Sahl
DWDavid M Wagner
David M Wagner
EGErin Graf
Erin Graf
Melioidosis, an infection caused by Burkholderia pseudomallei, has a very high risk of mortality when treated, with an even higher risk of fatality if undiagnosed or not treated appropriately. It is endemic to Asia, Australia, South America, and the Caribbean; however, the number of melioidosis cases reported in the United States has been increasing. Therefore, physicians should be aware of this clinical entity and its possible presentations. Mycotic aneurysms due to B. pseudomallei are extremely rare, accounting for ~1%–2% of cases. Here we describe a rare case of melioidosis presenting as a mycotic aneurysm in the United States, highlight the potential for diagnostic challenges and epidemiologic concerns, and provide a review of mycotic aneurysm cases due to B. pseudomallei published to date.

14 December 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLisa Speiser
Lisa Speiser
AWAlex M Wonnaparhown
Alex M Wonnaparhown
JBJanis Blair
Janis Blair
ASAmi Shah
Ami Shah
DPDharmendra R Patel
Dharmendra R Patel
MSMaria Teresa Seville
Maria Teresa Seville
Mpox, caused by infection with Monkeypox virus, usually presents as a mild, self-limited illness in immunocompetent persons that resolves within 2–4 weeks. Serious complications have been reported when mpox lesions involve vulnerable anatomic sites, such as the eye, and in those with substantial immunosuppression. We describe a patient with advanced human immunodeficiency virus infection and sustained viral shedding of mpox with ocular involvement, which resulted in vision loss.

27 September 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
WBWendelyn Bosch
Wendelyn Bosch
LSLisa Speiser
Lisa Speiser
NWNa Wi
Na Wi
KKKatherine S King
Katherine S King
TNTraci L Natoli
Traci L Natoli
YJYoung Juhn
Young Juhn
Background: The incidence of respiratory syncytial virus (RSV)–acute respiratory infection (ARI) in community-dwelling adults after the Omicron variant of the COVID-19 pandemic is unknown. Our aim was to assess the incidence of RSV-ARI in adults aged 18 to 64 years over 2 consecutive RSV seasons (October–April 2022–2024) in 4 US states. Methods: This community-based prospective cohort study comprised 7501 participants in Minnesota, Wisconsin, Florida, and Arizona. We calculated RSV-ARI and RSV–lower respiratory tract disease (LRTD) incidence and attack rates. We reported unadjusted incidence by age group, gender, race and ethnicity, Charlson Comorbidity Index, socioeconomic status, residential state, and rural/urban setting. Results: Seasons 1 and 2 had 2250 and 2377 ARI episodes, respectively, with an RSV-ARI positivity rate of 5.5% for season 1 and 5.8% for season 2 among those tested. In season 1, the overall incidence of RSV-ARI was 27.71 (95% CI, 22.82–33.34) per 1000 person-years (1.49% attack rate). Almost half (49.0%) had RSV-LRTD, with an incidence of 13.53 (95% CI, 10.19–17.61) per 1000 person-years (0.73% attack rate). In season 2, the RSV-ARI and RSV-LRTD incidence rates were 26.39 (95% CI, 21.73–31.75) per 1000 person-years (1.51% attack rate) and 12.43 (95% CI, 9.31–16.26) per 1000 person-years (0.72% attack rate). RSV-ARI incidence peaked in November 2022 and December 2023. Conclusions: Our observations suggest that RSV-ARI incidence and seasonal pattern are shifting to prepandemic RSV epidemiology.

29 June 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
WBWendelyn Bosch
Wendelyn Bosch
KKKatherine S King
Katherine S King
NWNa Wi
Na Wi
DWDavid A. Watson,
David A. Watson,
CCColin L Colby
Colin L Colby
YJYoung Juhn
Young Juhn
Background: Data on respiratory syncytial virus (RSV) acute respiratory infection (ARI) among community-dwelling U.S. adults aged 18-64 years, particularly those with high-risk conditions (HRC), remain limited. This study estimated incidence and attack rates of RSV-ARI and RSV lower respiratory tract disease (LRTD) in adults with and without HRCs. Methods: A multi-state, community-based prospective cohort of adults aged 18–64 years with and without HRCs was followed from October 2022 to September 2024. Incidence rates and annual attack rates of RSV-ARI and RSV-LRTD were calculated by HRC presence and age group. Results: Of 3,375 adults with at least one HRC, the RSV-ARI incidence rate was 17.9 per 1,000 person-years (attack rates: year-1, 1.87%; year-2, 1.56%), compared with 14.8 per 1,000 person-years (year-1, 1.33%; year-2, 1.50%) among adults without HRCs. RSV-LRTD incidence was 10.0 per 1,000 person-years in adults with HRCs versus 5.7 per 1,000 person-years in those without. Asthma, congenital immunodeficiency, and immunosuppressive medication use were associated with increased incidence of RSV-ARI and RSV-LRTD; while adults with solid organ transplant and chronic kidney disease had a significantly higher incidence rate of RSV-LRTD compared to those without these conditions. Adults aged 18–49 years with HRCs had significantly higher RSV-LRTD incidence (9.6 vs. 4.3 per 1,000 person-years). After adjustment for age and sex, having ≥1 HRC was associated with a 62% increased RSV-LRTD risk, rising to 117% among adults aged 18–49 years. Conclusions: Adults with HRCs—particularly asthma, congenital immunodeficiency, chronic kidney disease, immunosuppressive medication use, and solid organ transplant—experienced higher RSV-ARI and RSV-LRTD incidence. The elevated RSV-LRTD burden was most pronounced in adults aged 18–49 years with HRCs.

18 July 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
DIDan Ilges
Dan Ilges
YFYakun Fu
Yakun Fu
DDDrew T. Dickinson
Drew T. Dickinson
JRJohn Robinson
John Robinson
LSLisa Speiser
Lisa Speiser
DNDavid P. Nicolau
David P. Nicolau

30 September 2022 in Cureus
Verified
Journal Article
Open access
LGLeah M. Grant
Leah M. Grant
SKSabirah N. Kasule
Sabirah N. Kasule
MSMadeline L. Singer
Madeline L. Singer
LSLisa Speiser
Lisa Speiser
HVHolenarasipur Vikram
Holenarasipur Vikram
A 58-year-old man with recently diagnosed coccidioidal meningitis presented to the ED with a five-day history of headache, photopsia, blurred vision, and worsening encephalopathy. His coccidioidal meningitis had responded well to fluconazole therapy, but three weeks later, he developed acute symptomatic worsening. Unfortunately, his clinical worsening coincided with Arizona's worst seasonal West Nile Virus (WNV) outbreak. He was ultimately found to have WNV neuroinvasive disease. Concurrent coccidioidal and WNV neuroinvasive diseases have not been described in the literature. Fortunately, he improved quickly to his normal baseline without neurologic deficits with supportive therapy for his WNV neuroinvasive disease and remains on lifelong antifungal therapy for coccidioidal meningitis.